Introduction: The overall survival of patients with multiple myeloma has improved with the advent of novel agents; however, multiple myeloma remains incurable. Combinations of standard-of-care agents such as immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies are increasingly used in earlier lines of therapy. Patients with disease that is refractory to multiple novel agents represent a population with high unmet medical need and for whom therapies with new mechanisms of action could be beneficial. Melphalan flufenamide (melflufen) has demonstrated encouraging activity in patients with relapsed and refractory multiple myeloma. Areas covered: This review provides an overview of the mechanism of action of melflufen, a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly delivers alkylating agents into tumor cells. It reviews key Phase I and II clinical trial data for melflufen in combination with dexamethasone as well as in triplet combinations with daratumumab or bortezomib. The safety profile of melflufen, which is characterized primarily by clinically manageable hematologic adverse events, is described. Expert opinion: Melflufen has potential to fill a gap in the myeloma treatment landscape by providing a new mechanism of action with clinically meaningful efficacy and a favorable safety profile in patients refractory to multiple novel agents.

Melflufen for relapsed and refractory multiple myeloma

Larocca A.;
2020-01-01

Abstract

Introduction: The overall survival of patients with multiple myeloma has improved with the advent of novel agents; however, multiple myeloma remains incurable. Combinations of standard-of-care agents such as immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies are increasingly used in earlier lines of therapy. Patients with disease that is refractory to multiple novel agents represent a population with high unmet medical need and for whom therapies with new mechanisms of action could be beneficial. Melphalan flufenamide (melflufen) has demonstrated encouraging activity in patients with relapsed and refractory multiple myeloma. Areas covered: This review provides an overview of the mechanism of action of melflufen, a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly delivers alkylating agents into tumor cells. It reviews key Phase I and II clinical trial data for melflufen in combination with dexamethasone as well as in triplet combinations with daratumumab or bortezomib. The safety profile of melflufen, which is characterized primarily by clinically manageable hematologic adverse events, is described. Expert opinion: Melflufen has potential to fill a gap in the myeloma treatment landscape by providing a new mechanism of action with clinically meaningful efficacy and a favorable safety profile in patients refractory to multiple novel agents.
2020
29
10
1069
1078
https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1808884
https://doi.org/10.1080/13543784.2020.1808884
Melflufen; melphalan flufenamide; relapsed/refractory multiple myeloma
Oriol A.; Larocca A.; Leleu X.; Hajek R.; Hassoun H.; Rodriguez-Otero P.; Paner A.; Schjesvold F.H.; Gullbo J.; Richardson P.G.
File in questo prodotto:
File Dimensione Formato  
[PUBLISHED Vsn.] Oiol et al - 2020 - Melflufen for relapsed and refractory multiple myeloma.pdf

Accesso aperto

Descrizione: [PUBLISHED Vsn.] Oiol et al. Expert Opin Investig Drugs . 2020 Oct;29(10):1069-1078. doi: 10.1080/13543784.2020.1808884. Epub 2020 Sep 29. PMID: 32924646. © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Available at / disponibile all’URL: https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1808884 | https://doi.org/10.1080/13543784.2020.1808884
Tipo di file: PDF EDITORIALE
Dimensione 1.33 MB
Formato Adobe PDF
1.33 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1769711
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 16
social impact